ReviewJournal of the American Society of Nephrology : JASN2026
Evaluation and Counseling of Living Kidney Donor Candidates.
Review in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Evaluation Practices in Living Kidney Donor Candidates.Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The evaluation of living kidney donor candidates is a complicated process to determine eligibility for donation and ensure that candidates are well-informed of postdonation risks, along with any uncertainty in risk estimations. The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors provided recommendations to assist transplant programs in the evaluation and care of donors before, during, and after donation. In this review, we highlight new research that has changed the landscape of the evaluation and counseling of donor candidates. In 2021, a race-neutral equation for eGFR aimed to promote health equity; however, relying solely on this measure to assess kidney function may lead to more Black candidates being excluded from living kidney donation. The role of genetic testing in the evaluation of donor candidates continues to evolve as evidence accumulates about the higher risk of kidney failure among biologically related donors. Recent recommendations emphasize targeted evaluation for familial monogenic kidney diseases and suggest offering apolipoprotein L1 genotyping to living kidney donors of African ancestry, although the implications of apolipoprotein L1 results for donor eligibility is an area of ongoing research and debate. In 2025, North American guidelines revised the BP threshold for diagnosing and treating hypertension from ≥140/90 to ≥130/80 mm Hg. This will have implications in the assessment of donor candidates, who may be more likely to be declined for donation or put on hold until these new BP targets are reached. Finally, new evidence supports that male donor candidates should be informed of the higher risk of testicular-related complications postdonation compared with nondonors. Policy makers, guidance workgroups, and transplant programs will need to consider how these findings influence local practices related to the evaluation, counseling, and care of donor candidates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.